Systematic review of metabolic syndrome biomarkers: A panel for early detection, management, and risk stratification in the West Virginian population

International Journal of Medical Sciences

Volumn 13, Issue 1, 2016, Pages 25-38

  Srikanthan, Krithika ^a   Feyh, Andrew ^a   Visweshwar, Haresh ^a   Shapiro, Joseph I ^a   Sodhi, Komal ^a  

^a MARSHALL UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Literature review; Metabolic syndrome

Indexed keywords

ADIPONECTIN; ARYLDIALKYLPHOSPHATASE 1; BIOLOGICAL MARKER; GHRELIN; HIGH DENSITY LIPOPROTEIN; INTERLEUKIN 10; INTERLEUKIN 6; LEPTIN; OXIDIZED LOW DENSITY LIPOPROTEIN ANTIBODY; PLASMINOGEN ACTIVATOR INHIBITOR 1; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR ALPHA; URIC ACID; ADIPOCYTOKINE; ADIPOQ PROTEIN, HUMAN; IL10 PROTEIN, HUMAN; REACTIVE OXYGEN METABOLITE; SERPINE1 PROTEIN, HUMAN; TUMOR NECROSIS FACTOR;

ANALYTICAL PARAMETERS; CORRELATIONAL STUDY; DISEASE ASSOCIATION; EARLY DIAGNOSIS; HUMAN; HYPERGLYCEMIA; HYPERTENSION; LEPTIN ADIPONECTIN RATIO; LIPID OXIDATION; METABOLIC SYNDROME X; NONHUMAN; OBESITY; PATIENT CARE; REVIEW; RISK ASSESSMENT; SYSTEMATIC REVIEW; UNITED STATES; BLOOD; INFLAMMATION; METABOLISM; PATHOLOGY; WEST VIRGINIA;

ADIPOKINES; ADIPONECTIN; BIOMARKERS; HUMANS; INFLAMMATION; INTERLEUKIN-10; LEPTIN; METABOLIC SYNDROME X; PLASMINOGEN ACTIVATOR INHIBITOR 1; REACTIVE OXYGEN SPECIES; TUMOR NECROSIS FACTOR-ALPHA; WEST VIRGINIA;

EID: 84953212495     PISSN: 14491907     EISSN: None     Source Type: Journal    
DOI: 10.7150/ijms.13800     Document Type: Review

References (152)

1. Ford ES. The metabolic syndrome and mortality from cardiovascular disease and all-causes: findings from the National Health and Nutrition Examination Survey II Mortality Study. Atherosclerosis. 2004; 173: 309-14.
2. Aguilar M, Bhuket T, Torres S, Liu B, Wong RJ. Prevalence of the metabolic syndrome in the United States, 2003-2012. Jama. 2015; 313: 1973-4.
3. Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA, et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute scientific statement. Current opinion in cardiology. 2006; 21: 1-6.
4. Alberti KG, Zimmet P, Shaw J. Metabolic syndrome--a new world-wide definition. A Consensus Statement from the International Diabetes Federation. Diabetic medicine: a journal of the British Diabetic Association. 2006; 23: 469-80.
5. Grundy SM, Brewer HB, Cleeman JI, Smith SC, Lenfant C, American Heart A, et al. Definition of metabolic syndrome: Report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition. Circulation. 2004; 109: 433-8.
6. Bhandari R, Kelley GA, Hartley TA, Rockett IR. Metabolic syndrome is associated with increased breast cancer risk: a systematic review with meta- analysis. International journal of breast cancer. 2014; 2014: 189384.
7. Ryo M, Nakamura T, Kihara S, Kumada M, Shibazaki S, Takahashi M, et al. Adiponectin as a biomarker of the metabolic syndrome. Circulation journal: official journal of the Japanese Circulation Society. 2004; 68: 975-81.
8. Deng Y, Scherer PE. Adipokines as novel biomarkers and regulators of the metabolic syndrome. Annals of the New York Academy of Sciences. 2010; 1212: E1-E19.
9. Furukawa S, Fujita T, Shimabukuro M, Iwaki M, Yamada Y, Nakajima Y, et al. Increased oxidative stress in obesity and its impact on metabolic syndrome. The Journal of clinical investigation. 2004; 114: 1752-61.
10. Raghavan S, Subramaniyam G, Shanmugam N. Proinflammatory effects of malondialdehyde in lymphocytes. Journal of leukocyte biology. 2012; 92: 1055-67.
11. Fernandez-Sanchez A, Madrigal-Santillan E, Bautista M, Esquivel-Soto J, Morales-Gonzalez A, Esquivel-Chirino C, et al. Inflammation, oxidative stress, and obesity. International journal of molecular sciences. 2011; 12: 3117-32.
12. Mayeux R. Biomarkers: potential uses and limitations. NeuroRx: The journal of the American Society for Experimental NeuroTherapeutics. 2004; 1: 182-8.
13. Dong M, Ren J. What fans the fire: insights into mechanisms of leptin in metabolic syndrome-associated heart diseases. Current pharmaceutical design. 2014; 20: 652-8.
14. Ghantous CM, Azrak Z, Hanache S, Abou-Kheir W, Zeidan A. Differential Role of Leptin and Adiponectin in Cardiovascular System. International journal of endocrinology. 2015; 2015: 534320.
15. Yang R, Barouch LA. Leptin signaling and obesity: cardiovascular consequences. Circulation research. 2007; 101: 545-59.
16. Tardiff JC. Cardiac hypertrophy: stressing out the heart. The Journal of clinical investigation. 2006; 116: 1467-70.
17. Thogersen AM, Soderberg S, Jansson JH, Dahlen G, Boman K, Nilsson TK, et al. Interactions between fibrinolysis, lipoproteins and leptin related to a first myocardial infarction. European journal of cardiovascular prevention and rehabilitation: official journal of the European Society of Cardiology, Working Groups on Epidemiology & Prevention and Cardiac Rehabilitation and Exercise Physiology. 2004; 11: 33-40.
18. Yoshinaga M, Sameshima K, Tanaka Y, Wada A, Hashiguchi J, Tahara H, et al. Adipokines and the prediction of the accumulation of cardiovascular risk factors or the presence of metabolic syndrome in elementary school children. Circulation journal: official journal of the Japanese Circulation Society. 2008; 72: 1874-8.
19. Lee SW, Jo HH, Kim MR, You YO, Kim JH. Association between metabolic syndrome and serum leptin levels in postmenopausal women. Journal of obstetrics and gynaecology: the journal of the Institute of Obstetrics and Gynaecology. 2012; 32: 73-7.
20. Gannage-Yared MH, Khalife S, Semaan M, Fares F, Jambart S, Halaby G. Serum adiponectin and leptin levels in relation to the metabolic syndrome, androgenic profile and somatotropic axis in healthy non-diabetic elderly men. European journal of endocrinology / European Federation of Endocrine Societies. 2006; 155: 167-76.
21. Yun JE, Kimm H, Jo J, Jee SH. Serum leptin is associated with metabolic syndrome in obese and nonobese Korean populations. Metabolism: clinical and experimental. 2010; 59: 424-9.
22. Martins Mdo C, Lima Faleiro L, Fonseca A. [Relationship between leptin and body mass and metabolic syndrome in an adult population]. Revista portuguesa de cardiologia: orgao oficial da Sociedade Portuguesa de Cardiologia = Portuguese journal of cardiology: an official journal of the Portuguese Society of Cardiology. 2012; 31: 711-9.
23. Lara-Castro C, Fu Y, Chung BH, Garvey WT. Adiponectin and the metabolic syndrome: mechanisms mediating risk for metabolic and cardiovascular disease. Current opinion in lipidology. 2007; 18: 263-70.
24. Kadowaki T, Yamauchi T, Kubota N, Hara K, Ueki K, Tobe K. Adiponectin and adiponectin receptors in insulin resistance, diabetes, and the metabolic syndrome. The Journal of clinical investigation. 2006; 116: 1784-92.
25. Matsuzawa Y, Funahashi T, Kihara S, Shimomura I. Adiponectin and metabolic syndrome. Arteriosclerosis, thrombosis, and vascular biology. 2004; 24: 29-33.
26. Spranger J, Kroke A, Mohlig M, Bergmann MM, Ristow M, Boeing H, et al. Adiponectin and protection against type 2 diabetes mellitus. Lancet. 2003; 361: 226-8.
27. Santaniemi M, Kesaniemi YA, Ukkola O. Low plasma adiponectin concentration is an indicator of the metabolic syndrome. European journal of endocrinology / European Federation of Endocrine Societies. 2006; 155: 745-50.
28. Baratta R, Amato S, Degano C, Farina MG, Patane G, Vigneri R, et al. Adiponectin relationship with lipid metabolism is independent of body fat mass: evidence from both cross-sectional and intervention studies. The Journal of clinical endocrinology and metabolism. 2004; 89: 2665-71.
29. Falahi E, Khalkhali Rad AH, Roosta S. What is the best biomarker for metabolic syndrome diagnosis? Diabetes & metabolic syndrome. 2013.
30. Hara K, Horikoshi M, Yamauchi T, Yago H, Miyazaki O, Ebinuma H, et al. Measurement of the high-molecular weight form of adiponectin in plasma is useful for the prediction of insulin resistance and metabolic syndrome. Diabetes care. 2006; 29: 1357-62.
31. Kotani K, Sakane N. Leptin:adiponectin ratio and metabolic syndrome in the general Japanese population. The Korean journal of laboratory medicine. 2011; 31: 162-6.
32. Cicero AF, Magni P, More M, Ruscica M, Borghi C, Strollo F, et al. Metabolic syndrome, adipokines and hormonal factors in pharmacologically untreated adult elderly subjects from the Brisighella Heart Study historical cohort. Obesity facts. 2012; 5: 319-26.
33. Finucane FM, Luan J, Wareham NJ, Sharp SJ, O'Rahilly S, Balkau B, et al. Correlation of the leptin:adiponectin ratio with measures of insulin resistance in non-diabetic individuals. Diabetologia. 2009; 52: 2345-9.
34. Cong WN, Golden E, Pantaleo N, White CM, Maudsley S, Martin B. Ghrelin receptor signaling: a promising therapeutic target for metabolic syndrome and cognitive dysfunction. CNS & neurological disorders drug targets. 2010; 9: 557-63.
35. Varela L, Vazquez MJ, Cordido F, Nogueiras R, Vidal-Puig A, Dieguez C, et al. Ghrelin and lipid metabolism: key partners in energy balance. Journal of molecular endocrinology. 2011; 46: R43-63.
36. Tesauro M, Schinzari F, Rovella V, Di Daniele N, Lauro D, Mores N, et al. Ghrelin restores the endothelin 1/nitric oxide balance in patients with obesity- related metabolic syndrome. Hypertension. 2009; 54: 995-1000.
37. Pulkkinen L, Ukkola O, Kolehmainen M, Uusitupa M. Ghrelin in diabetes and metabolic syndrome. International journal of peptides. 2010; 2010.
38. Ukkola O, Poykko SM, Antero Kesaniemi Y. Low plasma ghrelin concentration is an indicator of the metabolic syndrome. Annals of medicine. 2006; 38: 274-9.
39. Ukkola O. Ghrelin and metabolic disorders. Current protein & peptide science. 2009; 10: 2-7.
40. Ukkola O. Ghrelin and the metabolic balance. Journal of endocrinological investigation. 2005; 28: 849-52.
41. Tschop M, Weyer C, Tataranni PA, Devanarayan V, Ravussin E, Heiman ML. Circulating ghrelin levels are decreased in human obesity. Diabetes. 2001; 50: 707-9.
42. Bacha F, Arslanian SA. Ghrelin suppression in overweight children: a manifestation of insulin resistance? The Journal of clinical endocrinology and metabolism. 2005; 90: 2725-30.
43. Fagerberg B, Hulten LM, Hulthe J. Plasma ghrelin, body fat, insulin resistance, and smoking in clinically healthy men: the atherosclerosis and insulin resistance study. Metabolism: clinical and experimental. 2003; 52: 1460-3.
44. McLaughlin T, Abbasi F, Lamendola C, Frayo RS, Cummings DE. Plasma ghrelin concentrations are decreased in insulin-resistant obese adults relative to equally obese insulin-sensitive controls. The Journal of clinical endocrinology and metabolism. 2004; 89: 1630-5.
45. St-Pierre DH, Karelis AD, Coderre L, Malita F, Fontaine J, Mignault D, et al. Association of acylated and nonacylated ghrelin with insulin sensitivity in overweight and obese postmenopausal women. The Journal of clinical endocrinology and metabolism. 2007; 92: 264-9.
46. Binder BR, Christ G, Gruber F, Grubic N, Hufnagl P, Krebs M, et al. P lasminogenactivator inhibitor 1: physiological and pathophysiological roles. News in physiological sciences: an international journal of physiology produced jointly by the International Union of Physiological Sciences and the American Physiological Society. 2002; 17: 56-61.
47. Kraja AT, Province MA, Arnett D, Wagenknecht L, Tang W, Hopkins PN, et al. Do inflammation and procoagulation biomarkers contribute to the metabolic syndrome cluster? Nutrition & metabolism. 2007; 4: 28.
48. Paganelli F, Alessi MC, Morange P, Maixent JM, Levy S, Vague IJ. Relationship of plasminogen activator inhibitor-1 levels following thrombolytic therapy with rt-PA as compared to streptokinase and patency of infarct related coronary artery. Thrombosis and haemostasis. 1999; 82: 104-8.
49. Kruithof EK, Gudinchet A, Bachmann F. Plasminogen activator inhibitor 1 and plasminogen activator inhibitor 2 in various disease states. Thrombosis and haemostasis. 1988; 59: 7-12.
50. Malgorzewicz S, Skrzypczak-Jankun E, Jankun J. Plasminogen activator inhibitor-1 in kidney pathology (Review). International journal of molecular medicine. 2013; 31: 503-10.
51. Juhan-Vague I, Alessi MC, Mavri A, Morange PE. Plasminogen activator inhibitor-1, inflammation, obesity, insulin resistance and vascular risk. Journalof thrombosis and haemostasis: JTH. 2003; 1: 1575-9.
52. Bilgili S, Celebiler AC, Dogan A, Karaca B. Inverse relationship between adiponectin and plasminogen activator inhibitor-1 in metabolic syndrome patients. Endocrine regulations. 2008; 42: 63-8.
53. Vague P, Juhan-Vague I, Aillaud MF, Badier C, Viard R, Alessi MC, et al. Correlation between blood fibrinolytic activity, plasminogen activator inhibitor level, plasma insulin level, and relative body weight in normal and obese subjects. Metabolism: clinical and experimental. 1986; 35: 250-3.
54. Sakkinen PA, Wahl P, Cushman M, Lewis MR, Tracy RP. Clustering of procoagulation, inflammation, and fibrinolysis variables with metabolic factors in insulin resistance syndrome. American journal of epidemiology. 2000; 152: 897-907.
55. Alessi MC, Juhan-Vague I. PAI-1 and the metabolic syndrome: links, causes, and consequences. Arteriosclerosis, thrombosis, and vascular biology. 2006; 26: 2200-7.
56. Folsom AR, Qamhieh HT, Wing RR, Jeffery RW, Stinson VL, Kuller LH, et al. Impact of weight loss on plasminogen activator inhibitor (PAI-1), factor VII, and other hemostatic factors in moderately overweight adults. Arteriosclerosis and thrombosis: a journal of vascular biology / American Heart Association. 1993; 13: 162-9.
57. Kruszynska YT, Yu JG, Olefsky JM, Sobel BE. Effects of troglitazone on blood concentrations of plasminogen activator inhibitor 1 in patients with type 2 diabetes and in lean and obese normal subjects. Diabetes. 2000; 49: 633-9.
58. Billiet L, Doaty S, Katz JD, Velasquez MT. Review of hyperuricemia as new marker for metabolic syndrome. ISRN rheumatology. 2014; 2014: 852954.
59. McGillicuddy FC, dela Llera Moya M, Hinkle CC, Joshi MR, Chiquoine EH, Billheimer JT, et al. Inflammation impairs reverse cholesterol transport in vivo. Circulation. 2009; 119: 1135-45.
60. Ishizaka N, Ishizaka Y, Toda E, Nagai R, Yamakado M. Association between serum uric acid, metabolic syndrome, and carotid atherosclerosis in Japanese individuals. Arteriosclerosis, thrombosis, and vascular biology. 2005; 25: 1038-44.
61. Silva HA, Carraro JC, Bressan J, Hermsdorff HH. Relation between uric acid and metabolic syndrome in subjects with cardiometabolic risk. Einstein. 2015; 13: 202-8.
62. Clausen JO, Borch-Johnsen K, Ibsen H, Pedersen O. Analysis of the relationship between fasting serum uric acid and the insulin sensitivity index in a population-based sample of 380 young healthy Caucasians. European journal of endocrinology / European Federation of Endocrine Societies. 1998; 138: 63-9.
63. Rathmann W, Funkhouser E, Dyer AR, Roseman JM. Relations of hyperuricemia with the various components of the insulin resistance syndrome in young black and white adults: the CARDIA study. Coronary Artery Risk Development in Young Adults. Annals of epidemiology. 1998; 8: 250-61.
64. Tsunoda S, Kamide K, Minami J, Kawano Y. Decreases in serum uric acid by amelioration of insulin resistance in overweight hypertensive patients: effect of a low-energy diet and an insulin-sensitizing agent. American journal of hypertension. 2002; 15: 697-701.
65. Khitan Z, Kim DH. Fructose: a key factor in the development of metabolic syndrome and hypertension. Journal of nutrition and metabolism. 2013; 2013: 682673.
66. Johnson RJ, Segal MS, Sautin Y, Nakagawa T, Feig DI, Kang DH, et al. Potential role of sugar (fructose) in the epidemic of hypertension, obesity and the metabolic syndrome, diabetes, kidney disease, and cardiovascular disease. The American journal of clinical nutrition. 2007; 86: 899-906.
67. de Oliveira EP, Burini RC. High plasma uric acid concentration: causes and consequences. Diabetology & metabolic syndrome. 2012; 4: 12.
68. Viazzi F, Garneri D, Leoncini G, Gonnella A, Muiesan ML, Ambrosioni E, et al. Serum uric acid and its relationship with metabolic syndrome and cardiovascular risk profile in patients with hypertension: insights from the I-DEMAND study. Nutrition, metabolism, and cardiovascular diseases: NMCD. 2014; 24: 921-7.
69. Puig JG, Martinez MA. Hyperuricemia, gout and the metabolic syndrome. Current opinion in rheumatology. 2008; 20: 187-91.
70. Chen LY, Zhu WH, Chen ZW, Dai HL, Ren JJ, Chen JH, et al. Relationship between hyperuricemia and metabolic syndrome. Journal of Zhejiang University Science B. 2007; 8: 593-8.
71. Ford ES, Li C, Cook S, Choi HK. Serum concentrations of uric acid and the metabolic syndrome among US children and adolescents. Circulation. 2007; 115: 2526-32.
72. Soukup M, Biesiada I, Henderson A, Idowu B, Rodeback D, Ridpath L, et al. Salivary uric acid as a noninvasive biomarker of metabolic syndrome. Diabetology & metabolic syndrome. 2012; 4: 14.
73. Chiou WK, Wang MH, Huang DH, Chiu HT, Lee YJ, Lin JD. The relationship between serum uric acid level and metabolic syndrome: differences by sex and age in Taiwanese. Journal of epidemiology / Japan Epidemiological Association. 2010; 20: 219-24.
74. Rodrigues SL, Baldo MP, Capingana P, Magalhaes P, Dantas EM, Molina Mdel C, et al. Gender distribution of serum uric acid and cardiovascular risk factors: population based study. Arquivos brasileiros de cardiologia. 2012; 98: 13-21.
75. Aroor AR, McKarns S, Demarco VG, Jia G, Sowers JR. Maladaptive immune and inflammatory pathways lead to cardiovascular insulin resistance. Metabolism: clinical and experimental. 2013; 62: 1543-52.
76. Weiss TW, Arnesen H, Seljeflot I. Components of the interleukin-6 transsignalling system are associated with the metabolic syndrome, endothelial dysfunction and arterial stiffness. Metabolism: clinical and experimental. 2013; 62: 1008-13.
77. Chedraui P, Escobar GS, Perez-Lopez FR, Palla G, Montt-Guevara M, Cecchi E, et al. Angiogenesis, inflammation and endothelial function in postmenopausal women screened for the metabolic syndrome. Maturitas. 2014; 77: 370-4.
78. Indulekha K, Surendar J, Mohan V. High sensitivity C-reactive protein, tumor necrosis factor-alpha, interleukin-6, and vascular cell adhesion molecule-1 levels in Asian Indians with metabolic syndrome and insulin resistance (CURES-105). Journal of diabetes science and technology. 2011; 5: 982-8.
79. Kim HJ, Higashimori T, Park SY, Choi H, Dong J, Kim YJ, et al. Differential effects of interleukin-6 and -10 on skeletal muscle and liver insulin action in vivo. Diabetes. 2004; 53: 1060-7.
80. Musialik K. The influence of chosen adipocytokines on blood pressure values in patients with metabolic syndrome. Kardiologia polska. 2012; 70: 1237-42.
81. Balasoiu M, Balasoiu AT, Stepan AE, Dinescu SN, Avramescu CS, Dumitrescu D, et al. Proatherogenic adipocytokines levels in metabolic syndrome. Romanian journal of morphology and embryology = Revue roumaine de morphologie et embryologie. 2014; 55: 29-33.
82. Gormez S, Demirkan A, Atalar F, Caynak B, Erdim R, Sozer V, et al. Adipose tissue gene expression of adiponectin, tumor necrosis factor-alpha and leptin in metabolic syndrome patients with coronary artery disease. Internal medicine. 2011; 50: 805-10.
83. van Exel E, Gussekloo J, de Craen AJ, Frolich M, Bootsma-Van Der Wiel A, Westendorp RG, et al. Low production capacity of interleukin-10 associates with the metabolic syndrome and type 2 diabetes: the Leiden 85-Plus Study. Diabetes. 2002; 51: 1088-92.
84. Calcaterra V, De Amici M, Klersy C, Torre C, Brizzi V, Scaglia F, et al. Adiponectin, IL-10 and metabolic syndrome in obese children and adolescents. Acta bio-medica: Atenei Parmensis. 2009; 80: 117-23.
85. Esposito K, Pontillo A, Giugliano F, Giugliano G, Marfella R, Nicoletti G, et al. Association of low interleukin-10 levels with the metabolic syndrome in obese women. The Journal of clinical endocrinology and metabolism. 2003; 88: 1055-8.
86. Chen LX, Zhang SD, Zhu LL, Sun M. [Association of metabolic syndrome with serum interleukin-10 and high sensitive C reactive protein(hs-CRP) in old men]. Zhong nan da xue xue bao Yi xue ban = Journal of Central South University Medical sciences. 2008; 33: 970-4.
87. Choi KM, Ryu OH, Lee KW, Kim HY, Seo JA, Kim SG, et al. Serum adiponectin, interleukin-10 levels and inflammatory markers in the metabolic syndrome. Diabetes research and clinical practice. 2007; 75: 235-40.
88. Nishida M, Moriyama T, Sugita Y, Yamauchi-Takihara K. Interleukin-10 associates with adiponectin predominantly in subjects with metabolic syndrome. Circulation journal: official journal of the Japanese Circulation Society. 2007; 71: 1234-8.
89. Landar A, Zmijewski JW, Dickinson DA, Le Goffe C, Johnson MS, Milne GL, et al. Interaction of electrophilic lipid oxidation products with mitochondria in endothelial cells and formation of reactive oxygen species. American journal of physiology Heart and circulatory physiology. 2006; 290: H1777-87.
90. Pohjantahti-Maaroos H, Palomaki A, Kankkunen P, Laitinen R, Husgafvel S, Oksanen K. Circulating oxidized low-density lipoproteins and arterial elasticity: comparison between men with metabolic syndrome and physically active counterparts. Cardiovascular diabetology. 2010; 9: 41.
91. Kelly AS, Jacobs DR, Sinaiko AR, Moran A, Steffen LM, Steinberger J. Relation of circulating oxidized LDL to obesity and insulin resistance in children. Pediatric diabetes. 2010; 11: 552-5.
92. Sigurdardottir V, Fagerberg B, Hulthe J. Circulating oxidized low-density lipoprotein (LDL) is associated with risk factors of the metabolic syndrome and LDL size in clinically healthy 58-year-old men (AIR study). Journal of internal medicine. 2002; 252: 440-7.
93. Holvoet P, Lee DH, Steffes M, Gross M, Jacobs DR. Association between circulating oxidized low-density lipoprotein and incidence of the metabolic syndrome. Jama. 2008; 299: 2287-93.
94. Krzystek-Korpacka M, Patryn E, Hotowy K, Czapinska E, Majda J, Kustrzeba- Wojcicka I, et al. Paraoxonase (PON)-1 activity in overweight and obese children and adolescents: association with obesity-related inflammation and oxidative stress. Advances in clinical and experimental medicine: official organ Wroclaw Medical University. 2013; 22: 229-36.
95. Martinelli N, Micaglio R, Consoli L, Guarini P, Grison E, Pizzolo F, et al. Low levels of serum paraoxonase activities are characteristic of metabolic syndrome and may influence the metabolic-syndrome-related risk of coronary artery disease. Experimental diabetes research. 2012; 2012: 231502.
96. Yilmaz H, Sayar N, Yilmaz M, Gurkan U, Sesal C, Tosu R, et al. Serum paraoxonase 1 activity in women with metabolic syndrome. Kardiologia polska. 2010; 68: 1219-24.
97. Le Lay S, Simard G, Martinez MC, Andriantsitohaina R. Oxidative stress and metabolic pathologies: from an adipocentric point of view. Oxidative medicine and cellular longevity. 2014; 2014: 908539.
98. Koh KK, Park SM, Quon MJ. Leptin and cardiovascular disease: response to therapeutic interventions. Circulation. 2008; 117: 3238-49.
99. Anato V, Garmendia JV, Bianco NE, De Sanctis JB. Antihypertensive treatment decreased serum leptin levels in severe preeclampsia during pregnancy. Annals of nutrition & metabolism. 2001; 45: 190-2.
100. Fogari R, Derosa G, Zoppi A, Rinaldi A, Lazzari P, Fogari E, et al. Comparison of the effects of valsartan and felodipine on plasma leptin and insulin sensitivity in hypertensive obese patients. Hypertension research: official journal of the Japanese Society of Hypertension. 2005; 28: 209-14.
101. Koh KK, Quon MJ, Lee SJ, Han SH, Ahn JY, Kim JA, et al. Efonidipine simultaneously improves blood pressure, endothelial function, and metabolic parameters in nondiabetic patients with hypertension. Diabetes care. 2007; 30: 1605-7.
102. Ficek J, Kokot F, Chudek J, Adamczak M, Ficek R, Wiecek A. Influence of antihypertensive treatment with perindopril, pindolol or felodipinon plasma leptin concentration in patients with essential hypertension. Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme. 2002; 34: 703-8.
103. Ihara S, Shimamoto K, Watanabe H, Sakai R, Kawana M. An alpha1-receptor blocker reduces plasma leptin levels in hypertensive patients with obesity and hyperleptinemia. Hypertension research: official journal of the Japanese Society of Hypertension. 2006; 29: 805-11.
104. Glueck CJ, Fontaine RN, Wang P, Subbiah MT, Weber K, Illig E, et al. Metformin reduces weight, centripetal obesity, insulin, leptin, and low-density lipoprotein cholesterol in nondiabetic, morbidly obese subjects with body mass index greater than 30. Metabolism: clinical and experimental. 2001; 50: 856-61.
105. Kok P, Roelfsema F, Frolich M, van Pelt J, Meinders AE, Pijl H. Activation of dopamine D2 receptors lowers circadian leptin concentrations in obese women. The Journal of clinical endocrinology and metabolism. 2006; 91: 3236-40.
106. Huang F, Del-Rio-Navarro BE, Perez-Ontiveros JA, Ruiz-Bedolla E, Saucedo-Ramirez OJ, Villafana S, et al. Effect of six-month lifestyle intervention on adiponectin, resistin and soluble tumor necrosis factor-alpha receptors in obese adolescents. Endocrine journal. 2014; 61: 921-31.
107. Lee JM, Kim JH, Son HS, Hong EG, Yu JM, Han KA, et al. Valsartan increases circulating adiponectin levels without changing HOMA-IR in patients with type 2 diabetes mellitus and hypertension. The Journal of international medical research. 2010; 38: 234-41.
108. Miazgowski T, Dziwura-Ogonowska J, Safranow K, Iskierska K, Widecka K. Changes in adiponectin level and fat distribution in patients with type 2 diabetes. European journal of clinical investigation. 2014; 44: 192-9.
109. Hibuse T, Maeda N, Kishida K, Kimura T, Minami T, Takeshita E, et al. A pilot three-month sitagliptin treatment increases serum adiponectin level in Japanese patients with type 2 diabetes mellitus--a randomized controlled trial START-J study. Cardiovascular diabetology. 2014; 13: 96.
110. Sam S, Haffner S, Davidson MH, D'Agostino R, Sr., Perez A, Mazzone T. Pioglitazone-mediated changes in lipoprotein particle composition are predicted by changes in adiponectin level in type 2 diabetes. The Journal of clinical endocrinology and metabolism. 2012; 97: E110-4.
111. Phillips SA, Ciaraldi TP, Kong AP, Bandukwala R, Aroda V, Carter L, et al. Modulation of circulating and adipose tissue adiponectin levels by antidiabetic therapy. Diabetes. 2003; 52: 667-74.
112. Kim SG, Ryu OH, Kim HY, Lee KW, Seo JA, Kim NH, et al. Effect of rosiglitazone on plasma adiponectin levels and arterial stiffness in subjects with prediabetes or non-diabetic metabolic syndrome. European journal of endocrinology / European Federation of Endocrine Societies. 2006; 154: 433-40.
113. Li CJ, Zhang JY, Yu DM, Zhang QM. Adding glimepiride to current insulin therapy increases high-molecular weight adiponectin levels to improve glycemic control in poorly controlled type 2 diabetes. Diabetology & metabolic syndrome. 2014; 6: 41.
114. von Eynatten M, Liu D, Bluemm A, Schuster T, Baumann M, Lutz J, et al. Changes in adiponectin multimer distribution in response to atorvastatin treatment in patients with type 2 diabetes. Clinical endocrinology. 2009; 71: 27-32.
115. Stoeckli R, Chanda R, Langer I, Keller U. Changes of body weight and plasma ghrelin levels after gastric banding and gastric bypass. Obesity research. 2004; 12: 346-50.
116. Meric C, Aydogdu A, Tasci I, Deniz F, Baysan O, Serdar M, et al. Effects of valsartan treatment on serum ghrelin level and left ventricular mass index in patients with untreated primary hypertension. Anadolu kardiyoloji dergisi: AKD = the Anatolian journal of cardiology. 2014; 14: 234-8.
117. Kadoglou NP, Tsanikidis H, Kapelouzou A, Vrabas I, Vitta I, Karayannacos PE, et al. Effects of rosiglitazone and metformin treatment on apelin, visfatin, and ghrelin levels in patients with type 2 diabetes mellitus. Metabolism: clinical and experimental. 2010; 59: 373-9.
118. Gambineri A, Pagotto U, Tschop M, Vicennati V, Manicardi E, Carcello A, et al. Anti-androgen treatment increases circulating ghrelin levels in obese women with polycystic ovary syndrome. Journal of endocrinological investigation. 2003; 26: 629-34.
119. Kellokoski E, Poykko SM, Karjalainen AH, Ukkola O, Heikkinen J, Kesaniemi YA, et al. Estrogen replacement therapy increases plasma ghrelin levels. The Journal of clinical endocrinology and metabolism. 2005; 90: 2954-63.
120. Fogari R, Zoppi A, Mugellini A, Maffioli P, Lazzari P, Derosa G. Role of angiotensin II in plasma PAI-1 changes induced by imidapril or candesartan in hypertensive patients with metabolic syndrome. Hypertension research: official journal of the Japanese Society of Hypertension. 2011; 34: 1321-6.
121. Koiou E, Tziomalos K, Katsikis I, Delkos D, Tsourdi EA, Panidis D. Disparate effects of pharmacotherapy on plasma plasminogen activator inhibitor-1 levels in women with the polycystic ovary syndrome. Hormones. 2013; 12: 559-66.
122. Laufs U, Wassmann S, Schackmann S, Heeschen C, Bohm M, Nickenig G. Beneficial effects of statins in patients with non-ischemic heart failure. Zeitschrift fur Kardiologie. 2004; 93: 103-8.
123. Nicholls A, Scott JT. Effect of weight-loss on plasma and urinary levels of uric acid. Lancet. 1972; 2: 1223-4.
124. Choi HK, Soriano LC, Zhang Y, Rodriguez LA. Antihypertensive drugs and risk of incident gout among patients with hypertension: population based case-control study. Bmj. 2012; 344: d8190.
125. Tsouli SG, Liberopoulos EN, Mikhailidis DP, Athyros VG, Elisaf MS. Elevated serum uric acid levels in metabolic syndrome: an active component or an innocent bystander? Metabolism: clinical and experimental. 2006; 55: 1293-301.
126. Athyros VG, Elisaf M, Papageorgiou AA, Symeonidis AN, Pehlivanidis AN, Bouloukos VI, et al. Effect of statins versus untreated dyslipidemia on serum uric acid levels in patients with coronary heart disease: a subgroup analy sis ofthe GREek Atorvastatin and Coronary-heart-disease Evaluation (GREACE) study. American journal of kidney diseases: the official journal of the National Kidney Foundation. 2004; 43: 589-99.
127. Samuelsson L, Gottsater A, Lindgarde F. Decreasing levels of tumour necrosis factor alpha and interleukin 6 during lowering of body mass index with orlistat or placebo in obese subjects with cardiovascular risk factors. Diabetes, obesity & metabolism. 2003; 5: 195-201.
128. Gullestad L, Aukrust P, Ueland T, Espevik T, Yee G, Vagelos R, et al. Effect of high- versus low-dose angiotensin converting enzyme inhibition on cytokine levels in chronic heart failure. Journal of the American College of Cardiology. 1999; 34: 2061-7.
129. Fliser D, Buchholz K, Haller H, Olmesartan EUTo, Pravastatin in I, Atherosclerosis I. Antiinflammatory effects of angiotensin II subtype 1 receptor blockade in hypertensive patients with microinflammation. Circulation. 2004; 110: 1103-7.
130. Hyun B, Shin S, Lee A, Lee S, Song Y, Ha NJ, et al. Metformin Down-regulates TNF-alpha Secretion via Suppression of Scavenger Receptors in Macrophages. Immune network. 2013; 13: 123-32.
131. Sola S, Mir MQ, Lerakis S, Tandon N, Khan BV. Atorvastatin improves left ventricular systolic function and serum markers of inflammation in nonischemic heart failure. Journal of the American College of Cardiology. 2006; 47: 332-7.
132. Freeman DJ, Norrie J, Sattar N, Neely RD, Cobbe SM, Ford I, et al. Pravastatin and the development of diabetes mellitus: evidence for a protective treatment effect in the West of Scotland Coronary Prevention Study. Circulation. 2001; 103: 357-62.
133. Rezaie-Majd A, Maca T, Bucek RA, Valent P, Muller MR, Husslein P, et al. Simvastatin reduces expression of cytokines interleukin-6, interleukin-8, and monocyte chemoattractant protein-1 in circulating monocytes from hypercholesterolemic patients. Arteriosclerosis, thrombosis, and vascular biology. 2002; 22: 1194-9.
134. DeRijk RH, Petrides J, Deuster P, Gold PW, Sternberg EM. Changes in corticosteroid sensitivity of peripheral blood lymphocytes after strenuous exercise in humans. The Journal of clinical endocrinology and metabolism. 1996; 81: 228-35.
135. Abbasi SH, Hosseini F, Modabbernia A, Ashrafi M, Akhondzadeh S. Effect of celecoxib add-on treatment on symptoms and serum IL-6 concentrations in patients with major depressive disorder: randomized double-blind placebo- controlled study. Journal of affective disorders. 2012; 141: 308-14.
136. Jung SH, Park HS, Kim KS, Choi WH, Ahn CW, Kim BT, et al. Effect of weight loss on some serum cytokines in human obesity: increase in IL-10 after weight loss. The Journal of nutritional biochemistry. 2008; 19: 371-5.
137. Liakopoulos OJ, Dorge H, Schmitto JD, Nagorsnik U, Grabedunkel J, Schoendube FA. Effects of preoperative statin therapy on cytokines after cardiac surgery. The Thoracic and cardiovascular surgeon. 2006; 54: 250-4.
138. Stelmach I, Jerzynska J, Kuna P. A randomized, double-blind trial of the effect of glucocorticoid, antileukotriene and beta-agonist treatment on IL-10 serum levels in children with asthma. Clinical and experimental allergy: journal of the British Society for Allergy and Clinical Immunology. 2002; 32: 264-9.
139. Krakauer M, Sorensen P, Khademi M, Olsson T, Sellebjerg F. Increased IL-10 mRNA and IL-23 mRNA expression in multiple sclerosis: interferon-beta treatment increases IL-10 mRNA expression while reducing IL-23 mRNA expression. Multiple sclerosis. 2008; 14: 622-30.
140. Sarinho E, Medeiros D, Schor D, Rego Silva A, Sales V, Motta ME, et al. Production of interleukin-10 in asthmatic children after Beta-1-3-glucan. Allergologia et immunopathologia. 2009; 37: 188-92.
141. Rector RS, Warner SO, Liu Y, Hinton PS, Sun GY, Cox RH, et al. Exercise anddiet induced weight loss improves measures of oxidative stress and insulin sensitivity in adults with characteristics of the metabolic syndrome. American journal of physiology Endocrinology and metabolism. 2007; 293: E500-6.
142. Elkan AC, Sjoberg B, Kolsrud B, Ringertz B, Hafstrom I, Frostegard J. Gluten- free vegan diet induces decreased LDL and oxidized LDL levels and raised atheroprotective natural antibodies against phosphorylcholine in patients with rheumatoid arthritis: a randomized study. Arthritis research & therapy. 2008; 10: R34.
143. Hayek T, Attias J, Coleman R, Brodsky S, Smith J, Breslow JL, et al. The angiotensin- converting enzyme inhibitor, fosinopril, and the angiotensin II receptor antagonist, losartan, inhibit LDL oxidation and attenuate atherosclerosis independent of lowering blood pressure in apolipoprotein E deficient mice. Cardiovascular research. 1999; 44: 579-87.
144. Vasankari T, Ahotupa M, Toikka J, Mikkola J, Irjala K, Pasanen P, et al. Oxidized LDL and thickness of carotid intima-media are associated with coronary atherosclerosis in middle-aged men: lower levels of oxidized LDL with statin therapy. Atherosclerosis. 2001; 155: 403-12.
145. Turfaner N, Uzun H, Balci H, Ercan MA, Karter YH, Caner M, et al. Ezetimibe therapy and its influence on oxidative stress and fibrinolytic activity. Southern medical journal. 2010; 103: 428-33.
146. Chenevard R, Hurlimann D, Bechir M, Enseleit F, Spieker L, Hermann M, et al. Selective COX-2 inhibition improves endothelial function in coronary artery disease. Circulation. 2003; 107: 405-9.
147. Noll C, Messaoudi S, Milliez P, Samuel JL, Delcayre C, Janel N. Eplerenone administration has beneficial effect on hepatic paraoxonase 1 activity in diabetic mice. Atherosclerosis. 2010; 208: 26-7.
148. Carreon-Torres E, Rendon-Sauer K, Monter-Garrido M, Toledo-Ibelles P, Gamboa R, Menjivar M, et al. Rosiglitazone modifies HDL structure and increases HDL-apo AI synthesis and catabolic rates. Clinica chimica acta; international journal of clinical chemistry. 2009; 401: 37-41.
149. Wojcicka G, Jamroz-Wisniewska A, Marciniak A, Lowicka E, Beltowski J. The differentiating effect of glimepiride and glibenclamide on paraoxonase 1 and platelet-activating factor acetylohydrolase activity. Life sciences. 2010; 87: 126-32.
150. Gouedard C, Koum-Besson N, Barouki R, Morel Y. Opposite regulation of the human paraoxonase-1 gene PON-1 by fenofibrate and statins. Molecular pharmacology. 2003; 63: 945-56.
151. Costa LG, Giordano G, Furlong CE. Pharmacological and dietary modulators of paraoxonase 1 (PON1) activity and expression: the hunt goes on. Biochemical pharmacology. 2011; 81: 337-44.
152. Hong SC, Zhao SP, Wu ZH. Probucol up-regulates paraoxonase 1 expression in hepatocytes of hypercholesterolemic rabbits. Journal of cardiovascular pharmacology. 2006; 47: 77-81.